Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2026 · third_quarter · Q3
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
Source: Senate LDA
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; tariffs
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; tariffs
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Kidney Disease Education Access Expansion Act of 2026
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
Kidney Disease Education Access Expansion Act of 2026
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Medication Affordability and Patent Integrity Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
Medication Affordability and Patent Integrity Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act)
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
S.1040, to prohibit product hopping and for other purposes
S.1040, to prohibit product hopping and for other purposes
S.1040, to prohibit product hopping and for other purposes
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program. HR 10445, the Continuing Resolution and provisions related to the PRV program.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Creating Hope Reauthorization Act of 2024
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program. HR 10445, the Continuing Resolution and provisions related to the PRV program.
Creating Hope Reauthorization Act of 2024
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program.
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2026 · second_quarter · Q2
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2026 · first_quarter · Q1
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; tariffs
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · fourth_quarter · Q4
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · third_quarter · Q3
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
S.1040, to prohibit product hopping and for other purposes
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · second_quarter · Q2
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · first_quarter · Q1
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act)
HR 1262, S 932 Give Kids a Chance Act to renew PRV program
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · fourth_quarter · Q4
S. 150/H.R. 9070, the Affordable Prescriptions for Patients Act of 2023, and related House legislation.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program. HR 10445, the Continuing Resolution and provisions related to the PRV program.
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · third_quarter · Q3
S. 150/H.R. 9070, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · second_quarter · Q2
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program.
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · first_quarter · Q1
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening resources.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · fourth_quarter · Q4
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · third_quarter · Q3
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · second_quarter · Q2
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding newborn screening and related FY 2024 CDC appropriations. Legislation regarding kidney disease and in particular rare kidney disease.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2024 appropriations for CDC newborn screening resources.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. Legislation regarding the Orphan Drug Exemption within the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · first_quarter · Q1
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding newborn screening and related FY 2024 CDC appropriations. Legislation regarding kidney disease and in particular rare kidney disease.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2022 · fourth_quarter · RA
Issues related to rare disease research, detection, diagnosis, treatment, care, and reimbursement.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2022 · fourth_quarter · Q4
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5376 Build Back Better Act/Inflation Reduction Act. H.R. 7667, the Food and Drug Amendments of 2022 and related Senate legislation. H.R.2471, Consolidated Appropriations Act, 2022 including the Food and Drug Omnibus Reform Act.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 and FY 2023 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act.
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
S.1040, to prohibit product hopping and for other purposes
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease.
S.1040, to prohibit product hopping and for other purposes
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2024 appropriations for CDC newborn screening resources.
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2024 appropriations for CDC newborn screening resources.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; H.R. 3893, Coordination, Accountability, Research, and Equity for All Kidneys Act of 2021. Congressional consideration of the Prescription Drug User Fee Act. H.R. 6963, Accelerated Approval Integrity Act, and H.R. 6996, Accelerated Access for Patient Act, and Senate proposals regarding expedited FDA pathways. H.R. 7506, the New Era of Preventing End-Stage Kidney Disease. H.R.2471, Consolidated Appropriations Act, 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE